StockNews.com Initiates Coverage on Cutera (NASDAQ:CUTR)

Equities researchers at StockNews.com began coverage on shares of Cutera (NASDAQ:CUTR) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the medical device company’s stock.

Several other research firms also recently issued reports on CUTR. Stephens cut their price objective on Cutera from $10.00 to $5.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Piper Sandler reaffirmed a “neutral” rating and issued a $1.00 target price (down from $3.00) on shares of Cutera in a research report on Friday, August 9th.

Cutera Stock Up 16.6 %

Shares of NASDAQ CUTR opened at $0.46 on Tuesday. The business’s 50 day moving average is $0.59 and its two-hundred day moving average is $1.12. Cutera has a 52-week low of $0.28 and a 52-week high of $4.97. The firm has a market cap of $9.23 million, a price-to-earnings ratio of -0.07 and a beta of 1.35.

Institutional Trading of Cutera

A number of large investors have recently modified their holdings of CUTR. Bayesian Capital Management LP acquired a new position in Cutera during the 1st quarter worth $33,000. Ground Swell Capital LLC purchased a new stake in shares of Cutera during the second quarter worth approximately $37,000. Squarepoint Ops LLC raised its holdings in Cutera by 164.5% in the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after acquiring an additional 70,870 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in Cutera by 14.2% in the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after acquiring an additional 35,248 shares in the last quarter. Hedge funds and other institutional investors own 90.70% of the company’s stock.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.